AlphAIalphai — Financial news for AI agents
manilatimes.netJUL 141 min read$PRCT

PROCEPT BioRobotics® to Report Second Quarter 2026 Financial Results on August 4th, 2026

PROCEPT BioRobotics (Nasdaq: PRCT) said it will release second-quarter 2026 financial results after market close on Aug. 4, 2026, and hold a conference call at 4:30 p.m. ET. The company noted its AQUABEAM and HYDROS robotic systems used for Aquablation therapy in urology.

Original reporting
manilatimes.net
Published Jul 14, 2026, 9:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 14, 2026, 9:28 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
PROCEPT BioRobotics® to Report Second Quarter 2026 Financial Results on August 4th, 2026 — source image
Source · manilatimes.net
Decision brief

The 30-second read

$PRCTNeutralMed
01

Why it matters

The primary tradable element is the fixed earnings date and call time, which can affect options pricing, hedging, and pre-earnings positioning.

02

Market read

This is a calendar catalyst for PRCT into Aug 4 after-hours, but it contains no new financial or operational datapoints.

03

What to watch

Volatility may be driven more by consensus estimate dispersion and any prior quarter surprises than by the mere existence of an earnings date, which this article does not address.

Relevance 5/10Novelty 5/10Timing: Ahead of the Aug 4, 2026 after-hours Q2 2026 earnings release and 4:30 p.m. ET call.

Background

The company is a surgical robotics firm focused on urology, including Aquablation therapy systems, and it is scheduling its Q2 2026 results release.

Company-level read

Ticker impact

$PRCTNeutralMedium confidence
Context

PROCEPT BioRobotics (PRCT) announced it will report Q2 2026 financial results after market close on Aug 4, 2026.

Expected impact

Likely modest pre-earnings positioning and higher implied volatility into the Aug 4 after-hours print; direction depends on the Q2 results and guidance not provided here.

Evidence & confidence

The article discloses only the timing of the upcoming earnings release and call, with no Q2 numbers, guidance, or new operational/regulatory developments.

Market effects

Sector

Provides a calendar catalyst for surgical robotics/urology medtech sentiment, but no sector-wide data or read-across is included.

Regional

No specific regional market linkage beyond US-listed earnings timing.

Global

Limited global relevance since the disclosure is company-specific scheduling with no international regulatory or trial updates.

Counterpoint

What could challenge this read

Because the release date is already a known type of event, traders may treat it as routine and focus only on any subsequent pre-announcement guidance or analyst revisions.

Key entities

  • company
    PROCEPT BioRobotics Corporation

    Nasdaq-listed surgical robotics company announcing Q2 2026 financial results timing and conference call details.

  • product
    AQUABEAM and HYDROS Robotic Systems

    Company systems referenced in the background section; no new product or clinical update is disclosed in this article.

Read at source← All news

Related articles

AUG 6
Med

PROCEPT BioRobotics Corporation Q2 2026 Earnings Call Summary

Procept BioRobotics reported Q2 2026 revenue up 19% year over year to $94.5 million, citing HYDROS system demand and record ASPs, while U.S. procedures grew 21% but missed expectations due to softness in legacy AQUABEAM accounts. Full-year 2026 revenue guidance remains $390 million to $410 million; U.S. procedures guidance lowered to 54,000–56,000. Management expects positive adjusted EBITDA in Q4 2026 and ongoing HYDROS replacement cycle through 2027.

yahoo.com6 min
JUL 30
$PRCTMedAI 8/10

Processa Pharmaceuticals Acquires Vidya Therapeutics and Secures $200 Million Financing to Advance BTK Inhibitor Pipeline

The acquisition transforms Processa's pipeline with the addition of clinical-stage BTK inhibitor VT-7208, while a concurrent $200 million private placement is expected to fund development into 2029. Key Investor Takeaways Processa Pharmaceuticals (NASDAQ:PRCT) acquired Vidya Therapeutics, adding clinical-stage BTK inhibitor VT-7208 to its pipeline. The company simultaneously secured a private placement expected to raise approximately $200 million to fund multiple Phase 2 clinical programs.

yahoo.com6 min
JUN 30
$PRCTMed

Evercore Initiates PROCEPT BioRobotics (PRCT) At “Outperform,” Cites Aquablation Growth Potential

PROCEPT BioRobotics (NASDAQ:PRCT) reported progress in its WATER IV prostate cancer program: enrollment completed for WATER IV RP (280 patients; Aquablation vs radical prostatectomy) with primary results expected at the AUA meeting in spring 2027, and FDA IDE approval for WATER IV AS (up to 333 patients; Aquablation vs active surveillance). Evercore ISI initiated coverage with an “Outperform” rating and $30 price target.

finance.yahoo.com4 min
AUG 8
$KRPMed

Kimbell Royalty Q2 Earnings Call Highlights

Kimbell Royalty (NYSE:KRP) reported record Q2 adjusted EBITDA of $84.9 million, with cash G&A of $5.9 million ($2.50 per BOE). It declared a $0.47 per common unit cash distribution, up 15% QoQ, and said 47% may be return of capital. The borrowing base rose to $660 million; debt was $478.7 million. Rig activity and production varied by basin.

yahoo.com6 min
AUG 8
$KMPRMed

Kemper Q2 Earnings Call Highlights

Kemper (NYSE:KMPR) reported Q2 results and discussed credit-loss allowances tied to surplus notes in its reciprocal exchange, including a $21 million pre-tax charge on $36 million of notes. Holding-company liquidity was $766 million and debt-to-capital rose to 28.3%. Personal auto normalized combined ratio was 102% and commercial 93.7%, with California rate actions and restructuring savings over $80 million run-rate.

yahoo.com6 min
AUG 8
$KOPMed

Koppers Q2 Earnings Call Highlights

Koppers (NYSE:KOP) reported Q2 updates on capital spending of about $24M, shareholder returns of $47M, and debt reduction of $22M in the first half. Liquidity was $390M with net debt of $857M and net leverage at 3.5x. The board raised its dividend to $0.09/share. KOP kept 2026 sales guidance at $1.9B-$2.0B but cut adjusted EBITDA to $240M-$250M and EPS to $3.80-$4.20.

yahoo.com6 min